Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.43 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27814421 | 0.85 | PARP1 (0.55) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| Hydrochloric Acid SCHEMBL27637867 | 0.84 | PARP1 (0.54) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL7102979 | 0.82 | PARP1 (0.52) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL28944768 | 0.81 | PARP1 (0.54) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL27823213 | 0.81 | PARP1 (0.54) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL4781388 | 0.81 | PARP1 (0.54) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL7673622 | 0.80 | PARP1 (0.54) | PARP1PARP2MAP4K4CSF1RPIM1 | |
| SCHEMBL4150950 | 0.80 | HSP90AA1 (0.44) | PARP1 | |
| SCHEMBL3013229 | 0.80 | PARP1 (0.40) | PARP1PARP2PARP3 | |
| SCHEMBL4359674 | 0.79 | KDM4E (0.45) | PARP1CYP2D6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750025-B2 | Derivatives of N-phenyl (piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-07-06 | — | — | US | disclosed |
| WO-2008018639-A2 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | WO | disclosed |
| US-7205319-B2 | exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2 | SANOFI-AVENTIS (FR) | 2007-04-17 | — | — | US | disclosed |
| US-20060223885-A1 | Derivatives of N-phenyl (piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-05 | — | — | US | disclosed |
| US-20050153963-A1 | N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy | SANOFI-AVENTIS (FR) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153963-A1 | N-[phenyl (piperidin-2-yl) methyl]benzamide derivatives, preparation thereof, and use thereof in therapy | HDAC6, NAT1, ARG2 | PARP1 341/4885PARP2 235/4885MAP4K4 3328/4885 |
| US-20060223885-A1 | Derivatives of N-phenyl (piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics | GABRE, CHRNA5, GRIN2B | PARP1 744/4885PARP2 697/4885MAP4K4 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.